Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A -r and NPM1c AML

Blood (2024) 143 (15): 1513–1527.

https://doi.org/10.1182/blood.2023021105

Published: 2024

Includes: Supplemental data

Journal Articles

PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy

Blood (2023) 142 (24): 2079–2091.

https://doi.org/10.1182/blood.2023020331

Published: 2023

Includes: Supplemental data

Journal Articles

T-Charge™ Manufacturing of the Anti-BCMA CAR-T, Durcabtagene Autoleucel (PHE885), Promotes Expansion and Persistence of CAR-T Cells with High TCR Repertoire Diversity

Shuntaro Ikegawa, Adam S. Sperling, Michela Ansuinelli, Sarah Nikiforow, David Quinn, Dexiu Bu, Jennifer Mataraza, David Pearson, Lawrence Rispoli, Marc A Credi, Nina Orwitz, Yohei Arihara, Rao Prabhala, Lakshmi Bhavani Potluri, Carol Reynolds, Serena De Vita, Nikhil C Munshi, Jerome Ritz

Blood (2023) 142 (Supplement 1): 3469.

https://doi.org/10.1182/blood-2023-177721

Published: 2023

Journal Articles

DNMT3A -Mutated Stem and Progenitor Cells Contribute to Altered T Cell Activation in Clonal Hematopoiesis

Ksenia R. Safina, Shawn David, Kyle A. Romine, Kristina D. Mujica, Daniel Ssozi, Jonathan Good, Nurefsan Sariipek, Yoke Seng Lee, Adrienne Parsons, Sarah Bibeau, Adam S. Sperling, Christopher James Gibson, Gabriel K. Griffin, Alexander G. Bick, Antonia Kreso, Jennifer J. Trowbridge, Peter van Galen

Blood (2023) 142 (Supplement 1): 1320.

https://doi.org/10.1182/blood-2023-180180

Published: 2023

Journal Articles

Heterogeneity in Access and Toxicity Management of Commercially Available BCMA-Directed CAR-T and Bispecific T-Cell Engager Therapy Among the International Myeloma Community

Blood (2023) 142 (Supplement 1): 7248.

https://doi.org/10.1182/blood-2023-184710

Published: 2023

Journal Articles

Phase II Trial of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Blood (2023) 142 (Supplement 1): 3382.

https://doi.org/10.1182/blood-2023-177947

Published: 2023

Journal Articles

Immuno-PRISM: A Randomized Phase II Platform Study of Bispecific Antibodies in High-Risk Smoldering Myeloma

Blood (2023) 142 (Supplement 1): 206.

https://doi.org/10.1182/blood-2023-177954

Published: 2023

Journal Articles

Expansion, Persistence, and Characteristics of Autologous, Bhv-1100 Armored Memory-like NK Cells Infused Prior to Autologous Stem Cell Transplant in MRD+ Multiple Myeloma Patients: A First-in-Human Trial

Blood (2023) 142 (Supplement 1): 2105.

https://doi.org/10.1182/blood-2023-180224

Published: 2023

Journal Articles

High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma

Mehmet Kemal Samur, Marco Roncador, Anil Aktas Samur, Mariateresa Fulciniti, Abdul Hamid Bazarbachi, Raphael Szalat, Masood A. Shammas, Adam S. Sperling, Paul G. Richardson, Florence Magrangeas, Stephane Minvielle, Aurore Perrot, Jill Corre, Philippe Moreau, Anjan Thakurta, Giovanni Parmigiani, Kenneth C. Anderson, Hervé Avet-Loiseau, Nikhil C. Munshi

Blood (2023) 141 (14): 1724–1736.

https://doi.org/10.1182/blood.2022017094

Published: 2023

Includes: Supplemental data

Journal Articles

UBR5 Is a Hect E3 Ubiquitin Ligase That Regulates Chromatin Bound Nuclear Hormone Receptor Stability

Blood (2022) 140 (Supplement 1): 2968–2969.

https://doi.org/10.1182/blood-2022-167615

Published: 2022

Journal Articles

Molecular Characterization of Adult Acute Lymphoblastic Leukemia Identifies a Subgroup with Myeloid Mutations and Pre-Existing Clonal Hematopoiesis

Blood (2022) 140 (Supplement 1): 1050–1052.

https://doi.org/10.1182/blood-2022-167977

Published: 2022

Journal Articles

Clonal hematopoiesis of indeterminate potential and risk of death from COVID-19

Blood (2022) 140 (18): 1993–1997.

https://doi.org/10.1182/blood.2022018052

Published: 2022

Includes: Supplemental data

Journal Articles

Lenalidomide promotes the development of TP53 -mutated therapy-related myeloid neoplasms

Blood (2022) 140 (16): 1753–1763.

https://doi.org/10.1182/blood.2021014956

Published: 2022

Includes: Supplemental data

Journal Articles

Association of clonal hematopoiesis with chronic obstructive pulmonary disease

Peter G. Miller, Dandi Qiao, Joselyn Rojas-Quintero, Michael C. Honigberg, Adam S. Sperling, Christopher J. Gibson, Alexander G. Bick, Abhishek Niroula, Marie E. McConkey, Brittany Sandoval, Brian C. Miller, Weiwei Shi, Kaushik Viswanathan, Matthew Leventhal, Lillian Werner, Matthew Moll, Brian E. Cade, R. Graham Barr, Adolfo Correa, L. Adrienne Cupples, Sina A. Gharib, Deepti Jain, Stephanie M. Gogarten, Leslie A. Lange, Stephanie J. London, Ani Manichaikul, George T. O’Connor, Elizabeth C. Oelsner, Susan Redline, Stephen S. Rich, Jerome I. Rotter, Vasan Ramachandran, Bing Yu, Lynette Sholl, Donna Neuberg, Siddhartha Jaiswal, Bruce D. Levy, Caroline A. Owen, Pradeep Natarajan, Edwin K. Silverman, Peter van Galen, Yohannes Tesfaigzi, Michael H. Cho, Benjamin L. Ebert, for the COPDGene Study Investigators, National Heart, Lung, and Blood Institute Trans-Omics for Precision Medicine Consortium

Blood (2022) 139 (3): 357–368.

https://doi.org/10.1182/blood.2021013531

Published: 2022

Includes: Supplemental data

Journal Articles

Quality of Life, Psychological Distress, and Prognostic Awareness in Patients with Multiple Myeloma

Elizabeth K. O'Donnell, Yael Shapiro, Omar Nadeem, Andrew J. Yee, Jacob P. Laubach, Andrew R. Branagan, Kenneth C. Anderson, Clifton C. Mo, Nikhil C. Munshi, Irene M. Ghobrial, Adam S. Sperling, Emerentia Agyemang, Cynthia C. Harrington, Jill N. Burke, Paul G. Richardson, Noopur S. Raje, Areej El-Jawahri

Blood (2021) 138 (Supplement 1): 4082.

https://doi.org/10.1182/blood-2021-146342

Published: 2021

Journal Articles

B-PRISM (Precision Intervention Smoldering Myeloma): A Phase II Trial of Combination of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Omar Nadeem, Robert A. Redd, Julia Prescott, Amada Metivier, Kelsey Tague, Veronica Romines, Meredith Bertoni, Alexandra Savell, Rebekah Medina, Alexandra Distaso, Houry Leblebjian, Clifton C. Mo, Jacob P. Laubach, Adam S. Sperling, Paul G. Richardson, Irene M. Ghobrial

Blood (2021) 138 (Supplement 1): 4782.

https://doi.org/10.1182/blood-2021-148023

Published: 2021

Journal Articles

Clonal Hematopoiesis Is Associated with Increased Risk of Progression of Asymptomatic Waldenström Macroglobulinemia

Sabrin Tahri, Tarek H Mouhieddine, Robert A. Redd, Luisa Maria Lampe, Katarina Nillson, Nang Kham Su, Habib El-Khoury, Amin H Nassar, Elio Adib, Govind Bindra, Sarah Abou Alaiwi, Lorenzo Trippa, David P. Steensma, Jorge J. Castillo, Steven P. Treon, Irene M. Ghobrial, Adam S. Sperling

Blood (2021) 138 (Supplement 1): 2678.

https://doi.org/10.1182/blood-2021-149711

Published: 2021

Journal Articles

A Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Omar Nadeem, Robert A. Redd, Julia Prescott, Kelsey Tague, Veronica Romines, Amada Metivier, Alexandra Savell, Houry Leblebjian, Alexandra Distaso, Clifton C Mo, Jacob P. Laubach, Adam S. Sperling, Paul G. Richardson, Irene M. Ghobrial

Blood (2021) 138 (Supplement 1): 2749.

https://doi.org/10.1182/blood-2021-149787

Published: 2021

Journal Articles

Phase I Study of PHE885, a Fully Human BCMA-Directed CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma Manufactured in <2 Days Using the T-Charge TM Platform

Blood (2021) 138 (Supplement 1): 3864.

https://doi.org/10.1182/blood-2021-146646

Published: 2021

Journal Articles

Infectious Complications in Patients Treated with Idecabtagene Vicleucel for Relapsed and Refractory Multiple Myeloma

Jessica S. Little, Parth Shah, Adam S. Sperling, Andrew R. Branagan, Omar Nadeem, Andrew J. Yee, Noopur S. Raje, Nikhil C. Munshi, Sarah Hammond

Blood (2021) 138 (Supplement 1): 3839.

https://doi.org/10.1182/blood-2021-153942

Published: 2021

NARROW

Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A -r and NPM1c AML

PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy

T-Charge™ Manufacturing of the Anti-BCMA CAR-T, Durcabtagene Autoleucel (PHE885), Promotes Expansion and Persistence of CAR-T Cells with High TCR Repertoire Diversity

DNMT3A -Mutated Stem and Progenitor Cells Contribute to Altered T Cell Activation in Clonal Hematopoiesis

Heterogeneity in Access and Toxicity Management of Commercially Available BCMA-Directed CAR-T and Bispecific T-Cell Engager Therapy Among the International Myeloma Community

Phase II Trial of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Immuno-PRISM: A Randomized Phase II Platform Study of Bispecific Antibodies in High-Risk Smoldering Myeloma

Expansion, Persistence, and Characteristics of Autologous, Bhv-1100 Armored Memory-like NK Cells Infused Prior to Autologous Stem Cell Transplant in MRD+ Multiple Myeloma Patients: A First-in-Human Trial

High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma

UBR5 Is a Hect E3 Ubiquitin Ligase That Regulates Chromatin Bound Nuclear Hormone Receptor Stability

Molecular Characterization of Adult Acute Lymphoblastic Leukemia Identifies a Subgroup with Myeloid Mutations and Pre-Existing Clonal Hematopoiesis

Clonal hematopoiesis of indeterminate potential and risk of death from COVID-19

Lenalidomide promotes the development of TP53 -mutated therapy-related myeloid neoplasms

Association of clonal hematopoiesis with chronic obstructive pulmonary disease

Quality of Life, Psychological Distress, and Prognostic Awareness in Patients with Multiple Myeloma

B-PRISM (Precision Intervention Smoldering Myeloma): A Phase II Trial of Combination of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Clonal Hematopoiesis Is Associated with Increased Risk of Progression of Asymptomatic Waldenström Macroglobulinemia

A Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Phase I Study of PHE885, a Fully Human BCMA-Directed CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma Manufactured in <2 Days Using the T-Charge TM Platform

Infectious Complications in Patients Treated with Idecabtagene Vicleucel for Relapsed and Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only